RT Journal
A1 Friedrich MJ
T1 HIv drugs and malaria
JF JAMA
JO JAMA
YR 2013
FD January 16
VO 309
IS 3
SP 223
OP 223
DO 10.1001/jama.2012.206200
UL http://dx.doi.org/10.1001/jama.2012.206200
AB 
In the open-label randomized trial, the participants—170 children aged 5 months to 5 years in Uganda who were infected with HIV—received antimalarial drugs and either of 2 anti-HIV therapies: the protease inhibitors lopinavir and ritonavir or non–nucleoside reverse transcriptase inhibitors (NNRTIs). Although neither regimen lowered the children's risk of developing malaria during the first 6 months of the study, risk of recurrence of malaria after successful treatment with the antimalarial drug artemether-lumefantrine was reduced by 41% in the group receiving protease inhibitors compared with those receiving NNRTIs. There was an increase in serious adverse events in the group receiving protease inhibitors.